Abstract: In one embodiment, an infrared (IR) imaging system for determining a concentration of a target species in an object is disclosed. The imaging system can include an optical system including an optical focal plane array (FPA) unit. The optical system can have components defining at least two optical channels thereof, said at least two optical channels being spatially and spectrally different from one another. Each of the at least two optical channels can be positioned to transfer IR radiation incident on the optical system towards the optical FPA. The system can include a processing unit containing a processor that can be configured to acquire multispectral optical data representing said target species from the IR radiation received at the optical FPA. Said optical system and said processing unit can be contained together in a data acquisition and processing module configured to be worn or carried by a person.

Abstract: Systems, methods, and computer program products for recursive modifications are provided. An example imaging system includes a first infrared (IR) imaging device that generates first IR image data of a first field of view of the first IR imaging device at a first time and a computing device operably connected with the first IR imaging device. The computing device receives the first IR image data from the first IR imaging device and determines a first set of pixels and a second set of pixels from amongst a plurality of pixels associated with the first IR image data. The computing device further determines a first modification protocol for the first set of pixels and determines a second modification protocol for the second set of pixels. In response, the computing device generates a recursive modification input based upon the first and second modification protocols.

Abstract: Provided herein are methods and compositions for treating and preventing inflammatory bowel disease.

Abstract: Techniques for data management are described. A monotonically increasing time source that indicates an elapsed time since a reference event may be activated. Multiple snapshots of a computing object may be generated in accordance with a schedule for backing up the computing object, where the schedule may include a retention duration for retaining snapshots. Based on generating the snapshots, timestamps for the snapshots may be stored, where the timestamps may indicate respective values of the monotonically increasing time source. As part of an expiration job, a reference value of the monotonically increasing time source may be identified based on the retention duration and a current value indicated by the monotonically increasing time source. Also, a snapshot of the snapshots may be expired based on a timestamp of the snapshot corresponding to a value of the monotonically increasing time source that is less than the reference value.

Abstract: The present disclosure relates to expression repressors decreasing expression of a target plurality of genes in a cell. In some embodiments, the target plurality of genes comprises CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL-8. In some embodiments, the expression repressor targets the E1 cRE of the CXCL locus. In some embodiments, the expression repressor targets the E2 cRE of the CXCL locus.

Abstract: Systems, methods, and computer program products for fugitive emission determinations are provided. An example imaging system includes a first infrared (IR) imaging device configured to generate first IR image data of a field of view of the first IR imaging device that include one or more data entries associated with a fugitive emission from an emission source. The system further includes a computing device operably connected with the first IR imaging device and configured to receive the first IR image data from the first IR imaging device, generate spectral absorption data based on the first IR image data, and determine a gas amount associated with the fugitive emission based upon the spectral absorption data. The computing device also determines a leak rate and leak duration of the fugitive emission based upon the determined gas amount and determines a total emission loss based on the same.

Abstract: The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Aspects of the disclosure relate to various liposomal compositions of oxazolidinone compounds, and related methods of manufacturing and using the oxazolidinone liposome compositions. In some embodiments, the liposome compositions have improved storage stability with regard to component degradation.

Abstract: Safe and effective exercise poses a specific set of challenges for subjects diagnosed with diabetes. These challenges include the coordination of exercise with blood glucose monitoring and insulin administration. Failure to coordinate these factors effectively can lead to various pathologies related to aberrant blood glucose levels. Presented herein are methods, systems, algorithms, computer program products, web portals, real-time live instruction, and computer-executable code for exercise guidance and instruction specific to diabetes relief and management. The systems as disclosed herein can help ameliorate, slow, or reduce a likelihood of developing a diabetic condition.

Abstract: The disclosed system provides a neuro-physiological assessment and rehabilitation system. The system selects, based on an injury type, one or more target regions of the patient's brain for assessment of a neurological metric associated with a neurological network of the patient's brain and a first predetermined visual stimulation is provided to the patient while first neurological data pertaining to the athletic performance of the patient reacting to the visual stimulation is received, including measurements pertaining to the neurological metric. The obtained first neurological data is compared to the baseline data threshold and a second visual stimulation configured to prompt the neurological metric toward the baseline data threshold is selected. Second neurological data pertaining to the athletic performance of the patient reacting to the second visual stimulation is received and a state of the neurological metric indicating whether the neurological metric adjusted toward the baseline threshold is provided.

Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).

Abstract: A system and method for determining a difficult venous access of a patient. Logic processes meta data acquired by a vasculature assessment device coupled with the patient. The meta data, e.g., vessel diameter, vessel depth, vessel wall thickness, vessel wall elasticity, tissue elasticity, tissue profusion, blood flow rate, or hydration level. The logic further determines a difficult venous access by performing an algorithm on the meta data. The algorithm is defined utilizing machine learning techniques applied to an ongoing collection data sets acquired from a plurality of systems across a plurality of patients undergoing catheter insertion events. The data set may also include patient data such as weight, age, etc. The vasculature assessment device may include ultrasound imaging, infrared imaging, molecular imaging, Raman spectroscopy, or optical coherence tomography to acquire one or both of three-dimensional imaging data and the meta data.

Abstract: Systems, methods, and computer program products for infrared (IR) image operations are provided. An example imaging system includes a first IR imaging device configured to generate first IR image data and a second IR imaging device configured to generate second IR image data. The system further includes a computing device that receives the first IR image data from the first IR imaging device and receives the second IR image data from the second IR imaging device. The computing device further determines a first feature representing a position of a gas plume based upon the first IR image data and a second feature representing a position of the gas plume based upon the second IR image data and determines a disparity between the first and second features. The computing device further determines a distance between the imaging system and the gas plume based upon the determined disparity.

Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Abstract: Systems, methods, and computer program products for fugitive emission determinations are provided. An example imaging system includes a first infrared (IR) imaging device configured to generate first IR image data of a field of view of the first IR imaging device that include one or more data entries associated with a fugitive emission from an emission source. The system further includes a computing device operably connected with the first IR imaging device and configured to receive the first IR image data from the first IR imaging device, generate spectral absorption data based on the first IR image data, and determine a gas amount associated with the fugitive emission based upon the spectral absorption data. The computing device also determines a leak rate and leak duration of the fugitive emission based upon the determined gas amount and determines a total emission loss based on the same.

Abstract: Various implementations provide a view of a 3D environment including a portal for viewing a stereo item (e.g., a photo or video) positioned a distance behind the portal. One or more visual effects are provided based on texture of one or more portions of the stereo item, e.g., texture at cutoff or visible edges of the stereo item. The effects change the appearance of the stereo item or the portal itself, e.g., improving visual comfort issues by minimizing window violations or otherwise enhancing the viewing experience. Various implementations provide a view of a 3D environment including an immersive view of a stereo item without using portal. Such a visual effect may be provided to partially obscure the surrounding 3D environment.

Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Abstract: The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.